Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nomraft is a generic raft-forming antacid formulation developed and manufactured by Acinom Healthcare. It is a combination product typically containing sodium alginate, sodium bicarbonate, and calcium carbonate. The primary mechanism of action involves the reaction of sodium alginate with gastric acid to form a thick, pH-neutral alginate gel, known as a 'raft,' which floats on the surface of the stomach contents. This raft serves as a physical barrier to prevent the reflux of acidic gastric contents into the esophagus. The sodium bicarbonate and calcium carbonate components react with stomach acid to release carbon dioxide, which becomes entrapped in the gel to provide buoyancy, while also providing a secondary antacid effect by neutralizing excess acid. Nomraft is indicated for the symptomatic relief of gastroesophageal reflux disease (GERD), heartburn, and acid indigestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nomraft.